Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
April 17, 2013 11:39 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based,
pharmaceutical company developing patient-friendly injectable
treatments for diabetes and other...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas
July 31, 2012 10:41 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
biopharmaceutical company developing patient-friendly injectable
treatments for diabetes...
PositiveID Corporation Finalizes First-in-Class Development of a Fully Synthetic Glucose Sensing System, a Critical Component of an Artificial Pancreas
March 05, 2012 08:00 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., March 5, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today that it has...